Laurence de Schoulepnikoff
Chief Operating Officer at OSE IMMUNOTHERAPEUTICS
Laurence de Schoulepnikoff active positions
Companies | Position | Start | End |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | Chief Operating Officer | 2022-01-15 | - |
Corporate Officer/Principal | 2021-12-19 | 2022-01-15 | |
Swiss Healthcare Licensing Group | Director/Board Member | - | - |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Chief Executive Officer | - | - |
Career history of Laurence de Schoulepnikoff
Former positions of Laurence de Schoulepnikoff
Companies | Position | Start | End |
---|---|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Chief Operating Officer | 2018-12-31 | - |
Training of Laurence de Schoulepnikoff
École Polytechnique Fédérale de Lausanne | Graduate Degree |
Statistics
International
Switzerland | 4 |
France | 3 |
Operational
Chief Operating Officer | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
OSE IMMUNOTHERAPEUTICS | Health Technology |
Private companies | 3 |
---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
Swiss Healthcare Licensing Group | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |